MOTS-c official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
The agency assessment found preclinical rather than treatment evidence
FDA’s July 2026 briefing did not identify studies administering the nominated MOTS-c substances to humans. It distinguished that absence from rodent and cell studies relevant to proposed metabolic and bone effects. FDA PDF pp. 25, 31 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Bone-cell findings do not establish fracture prevention
The discussed bone experiments used cultured cells and rodent models. They do not demonstrate reduced fractures or a clinical osteoporosis benefit in people. FDA PDF pp. 24, 31 ↗
Mechanistic uncertainty limits extrapolation
FDA noted missing in-vivo dose-response evaluation and uncertainty about the molecular targets. It considered the clinical relevance of the preclinical findings unresolved. FDA PDF pp. 25, 31 ↗
The recommendation concerns the nominated substances
The briefing weighed against inclusion of MOTS-c free base and acetate on the 503A bulks list and described characterization gaps. This staff proposal is distinct from a final agency action or an assessment of every related analogue. FDA PDF pp. 1, 32 ↗
What remains to be checked
- Check subsequent advisory records and any final FDA action separately from the staff briefing.
- Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
FDA mots-c briefing for the July 2026 advisory meeting ↗
Source dated 2026-07-23; retrieved 2026-09-19.
- The agency assessment found preclinical rather than treatment evidence · PDF pp. 25, 31 of 44
- Bone-cell findings do not establish fracture prevention · PDF pp. 24, 31 of 44
- Mechanistic uncertainty limits extrapolation · PDF pp. 25, 31 of 44
- The recommendation concerns the nominated substances · PDF pp. 1, 32 of 44
SHA-256:
5eec34a77c0dc06ffd0c570241b487137b5ce9b9200543ff19187d8f539a45da